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Achieving immediate release dosage forms
using DoE and Injection Moulding
Workflow:
Polymer problem:
Aim: to produce a solid oral dosage form that is both immediate release and has a homogeneous API dispersion
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Powder blends Hot Melt Extrusion Extrudate Injection Moulding Dosage forms
DSC:
 Dosage forms produced using polymers via 3D printing or Injection Moulding do not
behave in the same way as standard compressed powder tablets.
 Compressed powders have the ability to break apart of disintegrate increasing the particle
surface area to produce an immediate release of API
 Due to the complex polymer matrix this does not occur but instead either swelling of the
polymer where the drug can diffuse out or a slow erosion process
 Both these methods can hinder the release of drug
 To try and increase drug release rates disintegrating agents can be introduced to the
formulation which can either produce larger holes within the polymer matrix when the
agent dissolves are quicken the erosion process
 This study investigates a variety of disintegrating agents and small molecules to assess
their suitability to increase the rate of the erosion process of Polyvinyl Alcohol (PVA)
Hot Stage Microscope:
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Design of Experiments:
Figure 2: After excluding 3 
disintegrating agents from the 
initial DSC and HSM screen: 
NaCl, Glycine, Callulose, Klucel
ELF and Klucel HXF will be 
further analysed for their 
effectiveness as a disintegrant
Conclusion & Future Work:
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 The figure on the left (figure 4a) shows the DSC trace for the first heating cycle.
 A small endotherm can be observed at approximately 117°C corresponding to the melting of
Carvedilol. The peak is of relatively low intensity due to the small concentration of drug
present in the powder blend.
 The second heat cycle on the right (figure 4b) shows no events due to the drug becoming
amorphous and dissolving into the polymer.
 There is no degradation occurring for any of the disintegrating agents.
 DSC traces were obtained for raw PVA at different molecular weights (data not shown) to
determine which to use in the DoE. From this and solubility data PVA at Mw 13,000 was
chosen.
 Using the combination of HME and Injection Moulding solid oral dosage forms can be
produced however due to compaction pressure and the slowly eroding properties of the
polymers-immediate release can be difficult to achieve.
 Introducing disintegrating agents to the formulation is one possible route of increasing the
dissolution of the dosages.
 Design of Experiments is a useful statistical tool to obtain the most information from a
minimum number of experiments.
 The DSC and Hot Stage Microscope indicated that all agents chosen were compatible at the
temperature chosen to extrude at.
 A pharmaceutically irrelevant compound, small molecule, natural polymer and high and low
molecular weight synthetic polymers were chosen.
 The next steps is to extrude the formulations mentioned in figure 3 and to measure the
disintegrating time of the strand produced.
Hot Stage Microscope:
Fig 1a: Cellulose before heating
The melting of carvedilol (approx. 117°C) was observed for all powder blends as expected
according to the DSC traces (figure 3). However other events could be seen as the temperature
reached the maximum 200°C for blends containing Glycine and Klucel HXF. This is assumed to be
degradation of the disintegrating agent.
Exp No
Exp 
Name
Run 
Order
Incl/Excl API (%)
Disintegrting 
Agents (%)
1 N1 6 Incl 1 0
2 N2 5 Incl 20 0
3 N3 3 Incl 1 10
4 N4 4 Incl 20 10
5 N5 2 Incl 10.5 5
6 N6 1 Incl 10.5 5
Figure 3a: DSC traces for Cellulose blend 
(top) and Glycine blend (bottom) obtained 
from the first heat cycle 20-200°C
Figure 3b: DSC traces for Cellulose blend 
(top) and Glycine blend (bottom) obtained 
from the second heat cycle 20-200°C
Fig 1b:Cellulose blend showing the melting of carvedilol
Fig 1c: Glycine at 200°C before hold time Fig 1d: Glycine at 200°C after hold time
